

Product Data Sheet

Product Name: Sofetabart

Cat. No.: GC81527

Chemical Properties

Cas. No. 3066905-22-1

Formula M.Wt 145.23

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α (FR α). Sofetabart can be used to synthesize the antibody-drug conjugate (ADC) Sofetabart mipitecan. Sofetabart is applicable to research related to advanced ovarian cancer, platinum-resistant epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, as well as platinum-sensitive ovarian cancer [1] [2] [3] [4].

In Vitro, Sofetabart (LY-4170156 Antibody) serves as an FR α -targeting antibody for synthesizing the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

sofetabart mipitecan antibody-drug conjugate (ADC)^{[1][2][3][4]}.

References:

- [1]. O'Malley D, et al. Update from the phase I study of sofetabart mipitecan (Sofe-M), an antibody-drug conjugate (ADC) targeting folate receptor alpha (FR α) in advanced ovarian cancer (OC) [abstract]. ESMO Open. 2026;11(Suppl 6):108188.
- [2]. Coyle L. Industry Insights: Bioconjugate innovation gains momentum across partnerships and pivotal trials. Bioconjugate Insights. 2026;1(1):49-66.
- [3]. Moore KN, et al. Antibody-drug conjugates in gynaecological cancers: opportunities and challenges. Nature reviews. Clinical oncology. 2026 Jun 17.
- [4]. Ray-Coquard IL, et al. FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC). J Clin Oncol. 2026;44(16_suppl):TPS5644.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA